CHICAGO--(BUSINESS WIRE)--Aerogen, the global leader in aerosol drug delivery, today announced the results of a ground breaking study which showed a 32% reduction in the number of patients admitted to the hospital when treated with Aerogen® Solo vibrating mesh technology1. This breakthrough study demonstrates the impact of a high performance aerosol drug delivery system on patient care in the Emergency Department at St John’s Medical Center (Detroit, Michigan) and was presented simultaneously at both the American Association of Respiratory Care (San Antonio) and the American College of Emergency Physicians (Las Vegas).
The findings come at a time when Emergency Departments across the country are experiencing a sharp increase in the number of patients presenting with respiratory disorders such as COPD, asthma and influenza, which have more frequent exacerbations over the winter season2. The result is pressure on hospitals to increase the number of patients going through the Emergency Department.
“Reducing a patient’s need to be admitted means a couple of things. First, it means that patient feels a lot better and is ready to go home, which is great for the patient, but second, it also means one less person who may be waiting for a bed and spending some time in the hospital,” noted principal investigator and study co-author Robert Dunne, MD, Vice Chair of Emergency Medicine at St. John Medical Center.
The study looked at 1,576 patients over two sequential 30-day periods in a busy, urban emergency department. It compared the impact of bronchodilator medication administered with Aerogen® Solo vibrating mesh technology to treatments administered with a traditional small volume nebulizer. The research found that Aerogen technology was statistically associated with 32% fewer admissions to the hospital, a 75% reduction in the amount of medication administered and a 37-minute median reduction in the length of a patient’s stay in the Emergency Department.
“This large clinical study demonstrates the impact Aerogen technology can have in the Emergency Department and is further evidence of the outstanding clinical results we’ve seen when Aerogen technology is used in critical medical units all over the world,” noted John Power, Managing Director and CEO of Aerogen. “When patients feel better and can go home faster, without an extended hospital stay, it benefits everyone. This is truly great news for patients, clinicians and hospital administrators alike.”
Citation:
1.Dunne R et al. Aerosol dose matters in the Emergency Department: A comparison of impact of bronchodilator administration with two nebulizer systems. Poster at the American Association for Respiratory Care. 2016
2.Mackay AJ, Donaldson GC, Patel AR, Singh R, Kowlessar B and Wedzicha JA. Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2014;43:735-44.
Aerogen is the world’s leading medical device company specializing in the design, manufacture and commercialization of aerosol drug delivery systems. Aerogen’s patented vibrating mesh technology turns liquid medication into a fine particle mist, gently and effectively delivering drugs to the lungs of critically ill patients of all ages. Aerogen’s innovative products, such as the Aerogen® Solo and Aerogen® Ultra, significantly improve aerosol drug delivery resulting in better patient care throughout the Hospital.
Founded in Galway, Ireland in 1997, its North American offices are based in Chicago, Illinois. Aerogen has grown to become the global leader in high performance aerosol drug delivery and has partnered its technology with the leading mechanical ventilation companies. Aerogen technology is used by millions of patients and caregivers in over 75 countries worldwide. www.aerogen.com
PM328
